Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy

JCI insight - Tập 5 Số 12 - 2020
Pei-Hsuan Chen1, Mikel Lipschitz1, Jason L. Weirather1, Caron A. Jacobson2, Philippe Armand2, Kyle Wright3, F. Stephen Hodi1,2, Zachary J. Roberts4, Stuart A. Sievers4, John M. Rossi4, Adrian Bot4, William Y. Go4, Scott J. Rodig1,3
1Center for Immuno-Oncology and
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
3Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts USA.
4Kite, a Gilead company, Santa Monica, California, USA.

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1038/nrclinonc.2017.128

10.1186/s40425-018-0460-5

10.1056/NEJMra1706169

10.1016/j.ymthe.2016.10.020

10.1056/NEJMoa1708566

10.1111/imr.12243

10.1056/NEJMoa1215134

10.1056/NEJMoa1407222

10.1002/ajh.25403

10.1080/10428194.2017.1387905

10.1056/NEJMoa1707447

10.1016/S1470-2045(18)30900-8

[No authors listed]. YESCARTA Prescribing Information. YESCARTA. https://www.yescarta.com/files/yescarta-pi.pdf Accessed May 27, 2020

10.1016/j.beha.2018.07.011

10.1200/JCO.2017.35.15_suppl.3025

Rossi, 2018, Clinical response in ZUMA-1, the pivotal study of axicabtagene ciloleucel (Axi-Cel) in patients with refractory large B cell lymphoma, may be influenced by characteristics of the pretreatment tumor microenvironment (TME), Clin Lymphoma Myeloma Leuk, 18, 10.1016/j.clml.2018.07.213

Rossi, 2019, Abstract CT153: Pretreatment immunoscore and an inflamed tumor microenvironment (TME) are associated with efficacy in patients (Pts) with refractory large B cell lymphoma treated with axicabtagene ciloleucel (Axi-Cel) in ZUMA-1, Cancer Res, 79

10.1016/j.blre.2018.11.002

10.1016/S1470-2045(18)30864-7

Locke, 2017, Abstract CT020: Immune signatures of cytokine release syndrome and neurologic events in a multicenter registrational trial (ZUMA-1) in subjects with refractory diffuse large B cell lymphoma treated with axicabtagene ciloleucel (KTE-C19), Cancer Res, 77

10.1038/s41586-019-1325-x

10.1038/s41586-019-1324-y

10.1038/nri1961

10.1002/ajh.25445

Habermann, 2012, New developments in the management of diffuse large B-cell lymphoma, Hematology, 17 Suppl 1, S93, 10.1179/102453312X13336169156014

10.1016/j.hoc.2019.03.001

10.1634/theoncologist.2018-0028

10.1182/blood-2011-10-384388

10.1038/nature21405

10.1200/JCO.2014.56.2025

10.1038/ni.3682

10.1038/s41591-018-0041-7

10.1038/s41591-018-0036-4

Obstfeld, 2017, Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights, Blood, 130, 2569, 10.1182/blood-2017-08-802413

10.1182/bloodadvances.2019000600

10.1084/jem.20170580

10.1073/pnas.1715118115

Hashwah, 2019, The IL-6 signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large B-cell lymphoma, EMBO Mol Med, 11, 10.15252/emmm.201910576

10.1182/bloodadvances.2017012534

10.1158/2159-8290.CD-18-0367

10.1182/blood-2016-09-738245

10.1172/JCI94306

10.1172/JCI125423

10.1158/2159-8290.CD-17-0833

10.1038/s41591-018-0045-3

10.1182/blood-2018-10-881722

10.1016/j.cell.2017.01.016

10.1172/JCI126397

10.1158/1078-0432.CCR-15-1527

10.1126/scitranslmed.aaf8621

10.1002/cbin.10631

10.1016/j.ymeth.2014.08.016

Patel, 2019, The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative, Blood, 134, 2059

10.1182/blood-2017-03-770719

10.1038/s41586-018-0792-9